Neutrophil to Lymphocyte Ratio is Associated With Outcome During Ipilimumab Treatment()

BACKGROUND: Ipilimumab (IPI) and BRAF inhibitors (BRAFi) improve survival in melanoma, but not all patients will benefit and toxicity can be significant. Pretreatment neutrophil to lymphocyte ratio (NLR) has been associated with outcome in IPI-treated patients, but has not been studied during treatm...

Descripción completa

Detalles Bibliográficos
Autores principales: Cassidy, Michael R., Wolchok, Rachel E., Zheng, Junting, Panageas, Katherine S., Wolchok, Jedd D., Coit, Daniel, Postow, Michael A., Ariyan, Charlotte
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5405176/
https://www.ncbi.nlm.nih.gov/pubmed/28356222
http://dx.doi.org/10.1016/j.ebiom.2017.03.029

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5405176/
https://www.ncbi.nlm.nih.gov/pubmed/28356222
http://dx.doi.org/10.1016/j.ebiom.2017.03.029

Ejemplares similares